The Practical Side Effects Experienced in Patients Treated With Medications Approved for Melanoma.

IF 1.5 4区 医学 Q3 DERMATOLOGY
Advaitaa Ravipati, Tejus Pradeep, Philippe Jean-Pierre, Keyvan Nouri
{"title":"The Practical Side Effects Experienced in Patients Treated With Medications Approved for Melanoma.","authors":"Advaitaa Ravipati, Tejus Pradeep, Philippe Jean-Pierre, Keyvan Nouri","doi":"10.36849/JDD.8368","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Melanoma continues to remain one of the most feared malignancies among patients and dermatologists. Significant strides have been made in expanding the treatment arsenal with systemic medications and immunotherapeutics. With many more drugs available, side effects remain an important component of constructing treatment plans. Using the Food and Drug Administration (FDA) Adverse Events Reporting System (FAERS), cases of real-world side effects reported with melanoma medications were assessed to capture practical patient experiences. Treatments with the highest counts of adverse events were ipilimumab, nivolumab, dabrafenib, and vemurafenib. Individuals reported pyrexia (12.9%), rash (9.8%), diarrhea (9.5%), fatigue (7.0%), and colitis (6.7%) most frequently. Males were more likely to experience pyrexia (aOR 1.1, P=0.006), nausea (aOR 1.4, P&lt;0.001), rash (aOR 1.3, P&lt;0.001), vomiting (aOR 1.2, P=0.005), and headache (aOR 1.3, P&lt;0.001). Females had higher odds of fatigue (aOR 1.2, P=0.002), decreased appetite (aOR 1.2, P=0.004), and dyspnea (aOR 1.3, P&lt;0.001). Patients 62 years old or younger had higher odds of pyrexia (aOR 1.4, P&lt;0.001), nausea (aOR 1.2, P=0.001), vomiting (aOR 1.3, P&lt;0.001), and headache (aOR 2.9, P&lt;0.001). Individuals older than 62 were more likely to report diarrhea (aOR 1.2, P&lt;0.001), fatigue (aOR 1.4, P&lt;0.001), and decreased appetite (aOR 1.5, P&lt;0.001). With patients who have to already digest a difficult diagnosis, the ability to counsel individuals based on the practical side effects of treatments can pave the way for better dialogue and more trust.</p><p><strong>Citation: </strong>Ravipati A, Pradeep T, Jean-Pierre P, et al. The practical side effects experienced in patients treated with medications approved for melanoma. J Drugs Dermatol. 2025;24(5):539-542. doi:10.36849/JDD.8368.</p>","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"24 5","pages":"539-542"},"PeriodicalIF":1.5000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Drugs in Dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.36849/JDD.8368","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Melanoma continues to remain one of the most feared malignancies among patients and dermatologists. Significant strides have been made in expanding the treatment arsenal with systemic medications and immunotherapeutics. With many more drugs available, side effects remain an important component of constructing treatment plans. Using the Food and Drug Administration (FDA) Adverse Events Reporting System (FAERS), cases of real-world side effects reported with melanoma medications were assessed to capture practical patient experiences. Treatments with the highest counts of adverse events were ipilimumab, nivolumab, dabrafenib, and vemurafenib. Individuals reported pyrexia (12.9%), rash (9.8%), diarrhea (9.5%), fatigue (7.0%), and colitis (6.7%) most frequently. Males were more likely to experience pyrexia (aOR 1.1, P=0.006), nausea (aOR 1.4, P<0.001), rash (aOR 1.3, P<0.001), vomiting (aOR 1.2, P=0.005), and headache (aOR 1.3, P<0.001). Females had higher odds of fatigue (aOR 1.2, P=0.002), decreased appetite (aOR 1.2, P=0.004), and dyspnea (aOR 1.3, P<0.001). Patients 62 years old or younger had higher odds of pyrexia (aOR 1.4, P<0.001), nausea (aOR 1.2, P=0.001), vomiting (aOR 1.3, P<0.001), and headache (aOR 2.9, P<0.001). Individuals older than 62 were more likely to report diarrhea (aOR 1.2, P<0.001), fatigue (aOR 1.4, P<0.001), and decreased appetite (aOR 1.5, P<0.001). With patients who have to already digest a difficult diagnosis, the ability to counsel individuals based on the practical side effects of treatments can pave the way for better dialogue and more trust.

Citation: Ravipati A, Pradeep T, Jean-Pierre P, et al. The practical side effects experienced in patients treated with medications approved for melanoma. J Drugs Dermatol. 2025;24(5):539-542. doi:10.36849/JDD.8368.

经批准的黑色素瘤药物治疗患者的实际副作用。
背景:黑色素瘤仍然是患者和皮肤科医生最害怕的恶性肿瘤之一。在用全身药物和免疫疗法扩大治疗武器库方面取得了重大进展。有了更多的药物,副作用仍然是制定治疗计划的重要组成部分。使用美国食品和药物管理局(FDA)不良事件报告系统(FAERS),评估黑色素瘤药物报告的实际副作用病例,以获取实际患者经验。不良事件发生率最高的治疗是伊匹单抗、纳武单抗、达拉法尼和vemurafenib。个体报告最常见的是发热(12.9%)、皮疹(9.8%)、腹泻(9.5%)、疲劳(7.0%)和结肠炎(6.7%)。男性更容易出现发热(aOR 1.1, P=0.006)、恶心(aOR 1.4, P= 0.001)、皮疹(aOR 1.3, P= 0.001)、呕吐(aOR 1.2, P=0.005)和头痛(aOR 1.3, P= 0.001)。女性出现疲劳(aOR为1.2,P=0.002)、食欲下降(aOR为1.2,P=0.004)和呼吸困难(aOR为1.3,P= 0.001)的几率更高。62岁及以下患者出现发热(aOR为1.4,P < 0.001)、恶心(aOR为1.2,P=0.001)、呕吐(aOR为1.3,P < 0.001)和头痛(aOR为2.9,P < 0.001)的几率较高。年龄大于62岁的个体更有可能报告腹泻(aOR为1.2,P<0.001)、疲劳(aOR为1.4,P<0.001)和食欲下降(aOR为1.5,P<0.001)。对于那些已经不得不接受艰难诊断的病人来说,根据治疗的实际副作用向个人提供咨询的能力可以为更好的对话和更多的信任铺平道路。引文:Ravipati A, Pradeep T, Jean-Pierre P等。接受黑色素瘤药物治疗的患者所经历的实际副作用。皮肤医学杂志,2025;24(5):539-542。doi: 10.36849 / JDD.8368。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.20
自引率
13.30%
发文量
289
审稿时长
3-6 weeks
期刊介绍: The Journal of Drugs in Dermatology (JDD) is a peer-reviewed publication indexed with MEDLINE®/PubMed® that was founded by the renowned Dr. Perry Robins MD. Founded in 2002, it offers one of the fastest routes to disseminate dermatologic information and is considered the fastest growing publication in dermatology. We present original articles, award-winning case reports, and timely features pertaining to new methods, techniques, drug therapy, and devices in dermatology that provide readers with peer reviewed content of the utmost quality. Our high standards of content are maintained through a balanced, peer-review process. Articles are reviewed by an International Editorial Board of over 160 renowned experts.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信